Anebulo Pharmaceuticals Inc ANEB

$0.26 +0.02 (7.53%)

Valuation

Market cap
9,862,000
Revenue TTM
$0
Net income TTM
$-8,480,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
100
Avg volume
176
Day's range
$0.26 – $0.26
Shares out
40,785,000
Stochastic %K
38%
Beta
-1.88
Analysts
—
Price target
$3.00

Price

Company profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unme...

Show more

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
512 598 0931
Website
https://www.anebulo.com
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, United States

Latest news